MorphoSys receives first HuCAL Patent

01-Nov-2000

Munich, Germany, October 31, 2000

MorphoSys AG (Neuer Markt: MOR) announced today that the Australian Patent Office has granted a patent covering its proprietary Human Combinatorial Antibody Library (HuCAL) technology. The patent covers the design and the methods of making the HuCAL antibody libraries. The basic patent application had been filed under the PCT regulation (PCT: Patent Cooperation Treaty) in 1996, and the Australian patent is the first grant within the HuCAL patent family. Further patent applications are pending in the US, Canada, Japan and the European Patent Office.

"The Australian grant confirms the patentability of our HuCAL technology, and has precisely the scope that we requested," said Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. "We are confident that patents in similar form will soon issue in other jurisdictions."

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterisation. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers world-wide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Roche AG (Basel/Switzerland), DuPont Pharmaceuticals (Wilmington, Delaware/USA), Millennium (Cambridge, Mass/USA), Chiron (Emeryville, California/USA), GPC Biotech AG (Munich/Germany) ProChon Biotech (Revohot/Israel), Eos Biotechnology (South San Francisco/California/USA) and ImmunoGen (Cambridge, Mass/USA).

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, ?forward-looking statements? for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including ?anticipates?, ?believes?, ?intends?, ?estimates?, ?expects? and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company?s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company?s proprietary rights and other factors described in the prospectus relating to the company?s recent public offering.

https://www.chemeurope.com/en/news/281/morphosys-receives-first-hucal-patent.html